Danziger Asaf 4
4 · NovoCure Ltd · Filed Jan 3, 2025
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Danziger Asaf
Director
Transactions
- Award
Ordinary Shares
2024-12-31$14.75/sh+412$6,076→ 15,640 total - Award
Ordinary Shares
2025-01-01+400,000→ 415,640 total
Footnotes (3)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).
- [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.
- [F3]Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates.